Clinical trials: Recurrent GBM
Brain and Central Nervous System Tumors
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
Phase I/II trial to study the effectiveness of pyrazoloacridine plus carboplatin in treating patients who have recurrent glioma.
- Trial name
- NCT00005976
- Testing
- carboplatin, pyrazoloacridine
- Where
- 23 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Glioblastoma
CUE-102 in Recurrent Glioblastoma
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM).
- Conditions
- Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
- Trial name
- NCT06917885
- Testing
- CUE-102
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- David Reardon, MD
Recurrent Glioblastoma
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI).
- Trial name
- NCT05284643
- Testing
- Intensity Modulated Proton Therapy (IMPT), Bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Miami
Glioblastoma Multiforme, Glioma of Brain
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose…
- Trial name
- NCT03834740
- Testing
- Ribociclib, Everolimus
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Glioma, Glioblastoma
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
This Phase 0 surgical window of opportunity trial seeks to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) properties of an FDA-approved proprotein convertase/ kexin type 9 serine protease inhibitor (PCSK9i) in…
- Trial name
- NCT04937413
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Recurrent Glioblastoma
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent…
- Trial name
- NCT05118776
- Testing
- ASC40 tablets, Bevacizumab
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive…
- Trial name
- NCT01906385
- Testing
- Rhenium Liposome Treatment
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cerenome
Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00045708
- Testing
- ixabepilone, pharmacological study, Anticonvulsant
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Adult Glioblastoma
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling.
- Trial name
- TGEN (NCT02060890)
- Testing
- specialized tumor board recommendation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Glioblastoma Multiforme
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells.
- Trial name
- NCT00104091
- Testing
- TP-38
- Volunteers
- 56 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Recurrence of Solid Tumor, Glioblastoma Multiforme
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
This is a non-randomized two-part study of MK-4827 given with temozolomide in participants with advanced cancer. In Part A of the study, the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of MK-4827 when…
- Conditions
- Recurrence of Solid Tumor, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT01294735
- Testing
- MK-4827, Temozolomide
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT06410248
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Northwestern University
Glioblastoma
Metronomic Temozolamide in Patients With Recurrent Glioblastoma
Indication: Subjects with glioblastoma at first relapse after surgery, radiotherapy and first-line temozolomide (TMZ). Objectives: 1.
- Trial name
- NCT01308632
- Testing
- Temozolamide, irinotecan
- Volunteers
- 30 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Ependymoma, Glioblastoma
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
This phase I trial investigates the side effects of brain tumor-specific immune cells (IL13Ralpha2-CAR T cells) in treating patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma.
- Conditions
- Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT04661384
- Testing
- IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00516607
- Testing
- enzastaurin hydrochloride, temozolomide, pharmacological study
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00238303
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG)
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
- Conditions
- High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
- Trial name
- NCT07455045
- Testing
- FZ-AD005
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Recurrent Glioblastoma
A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma.
- Trial name
- NEO-GLITIPNI (NCT06097975)
- Testing
- Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV, Neurosurgery and intracavitary injection nivolumab and ipililumab, Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitair Ziekenhuis Brussel